CFAP418

CFAP418 encodes a protein that is present throughout the body but reaches especially high levels in the brain, heart, and retina. Inside retinal cells, the protein sits at the base of the primary cilium, a tiny antenna-like structure that photoreceptors (the retina's light-detecting cells) depend on. The gene was renamed from C8orf37, so most published research still uses the older name. Laboratory research in mice suggests the protein helps manage fatty molecules (lipids) in cell membranes, and losing it disturbs membrane balance and mitochondria, the parts of the cell that produce energy. Studies in mice also show the protein is needed to build the stacked discs inside photoreceptors that capture light. In cell and tissue studies it partners with another photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.)-survival protein called FAM161A.

In people with a retinitis pigmentosa pattern, the first symptoms reported have been night blindness followed by gradual narrowing of the visual field. In people with a cone-rod dystrophy pattern, early symptoms have instead included sensitivity to light and loss of central sharpness. A recurring feature across both patterns is early involvement of the macula, the central part of the retina responsible for detailed vision. Symptoms in reported patients began in infancy in some families and in adolescence in others. Some individuals have also been described with high myopia (severe near-sightedness) and early cataracts. The severity and course can vary considerably, even among relatives who carry the same genetic change.

The link between CFAP418 and inherited retinal disease is well established, and the gene is included in clinical reference resources for retinitis pigmentosa. Disease-causing changes have been reported in families from many parts of the world, including Pakistan, India, Thailand, Japan, and Jordan. The same gene can produce either a retinitis pigmentosa presentation or a cone-rod dystrophy presentation, reflecting how closely these two conditions overlap. Because the protein works within the primary cilium, changes in this gene can extend beyond the eye and cause the broader ciliopathy (definition: A disease caused by a problem with cilia — tiny hair-like structures on cells, including the light-sensing cells in the retina, that the cell needs to work properly.) known as Bardet-Biedl syndrome.

The precise job of the CFAP418 protein is still being worked out, and its function was long described as unknown. Whether it is best understood as a strictly ciliary protein is debated, because one mouse study found no defect in the connecting cilium and instead pointed to a role in transporting membrane proteins inside the cell. It is not currently possible to predict from the genetic result alone whether a given person will develop only eye involvement or the wider systemic features of Bardet-Biedl syndrome. Some observations, such as postaxial extra digits appearing mainly with certain splice-site changes, are based on small numbers of families and need confirmation.

No approved therapy currently targets CFAP418, and the research to date is aimed at understanding how the protein works rather than at treating people. Scientists have created mouse models that lose this gene and develop retinal degeneration resembling the human disease, giving a tool for future therapeutic testing. Laboratory work has begun to map the protein's partners and its handling of membrane lipids, which may point toward mechanisms that could eventually be targeted. These are early-stage findings in animals and cells, not treatments available to patients.

• How CFAP418 (C8orf37) was first linked to retinal disease

  Human genetic study with laboratory localization work.

  What was found:

  They identified disease-causing changes in C8orf37 and showed the protein localizes at the base of the cilium in retinal cells, with affected individuals having cone-rod dystrophy or retinitis pigmentosa with early macular involvement.

  Why it matters:

  This established the gene as a cause of inherited retinal disease and highlighted the role of ciliary processes.

  Limitation: The findings came from a small number of consanguineous families.

• Recognizing CFAP418 as a cause of Bardet-Biedl syndrome (BBS21)

  Human case report combined with animal (zebrafish) modeling.

  What was found:

  A loss-of-function change in C8ORF37 was found, and reducing the gene in zebrafish reproduced BBS-like features and impaired vision, defining BBS21.

  Why it matters:

  It confirmed that this gene can cause a body-wide ciliopathy, not only eye-limited disease.

  Limitation: Based on a single patient plus animal experiments, so it does not describe how often BBS occurs.

• What the protein does inside photoreceptors

  Preclinical laboratory and animal research.

  What was found:

  The protein binds specific lipids, and its loss disturbed membrane balance, harmed mitochondria, and disrupted several cell trafficking pathways.

  Why it matters:

  It offers a possible explanation for how changes in this gene damage the retina, which could guide future therapies.

  Limitation: Conducted in mice and cells; not yet shown to translate into a treatment for people.

• Detailed clinical features in patients with C8orf37 changes

  Observational human case series.

  What was found:

  Symptoms began in infancy or adolescence, with night blindness and field loss in the RP group and light sensitivity and vision loss in the cone-rod group, plus early macular atrophy; polydactyly in one family suggested a possible syndromic link.

  Why it matters:

  It shows the range of how the same gene can affect vision and hinted at wider ciliary involvement.

  Limitation: Very small number of patients and families.

• Hidden systemic features in presumed eye-only disease

  Observational human study with genotype-guided re-examination.

  What was found:

  A CFAP418 splice change was the most common genetic finding, and careful re-evaluation uncovered previously unrecognized features such as obesity, extra digits, and kidney anomalies, with wide variability even among relatives sharing the same change.

  Why it matters:

  It shows that some people labeled as having eye-only disease may actually have a broader syndrome that benefits from wider monitoring.

  Limitation: Single-region cohort of modest size, so results may not apply everywhere.

Because CFAP418 can cause Bardet-Biedl syndrome as well as eye-only disease, families may benefit from awareness that some people with changes in this gene also develop features such as extra fingers or toes, obesity, kidney abnormalities, or learning differences. Reported vision symptoms sometimes begin in infancy or childhood, which can make early attention to a child's development and schooling important. Since the condition is autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.), unaffected parents are typically carriers, and siblings may wish to discuss carrier or diagnostic testing with a genetics professional.

• Does my genetic result indicate a retinitis pigmentosa pattern, a cone-rod dystrophy pattern, or something that could include Bardet-Biedl syndrome?
• Given the specific CFAP418 changes I carry, what type of monitoring of my central and peripheral vision would you recommend?
• Should I be evaluated for non-eye features sometimes seen with this gene, such as kidney or metabolic involvement?
• What does autosomal recessive inheritance mean for my siblings, children, or other relatives?
• Are there imaging or functional tests that would help track how my vision changes over time?
• Are there any registries or studies you would suggest I look into?

Confirming the specific genetic changes and discussing what they mean for you and your relatives is best done with a genetic counselor or retinal specialist. Because this gene can be associated with body-wide features, a clinician may suggest checking for signs such as kidney or metabolic involvement. To explore studies that may be relevant, you can use RP Hope's Clinical Trials Finder with CFAP418 preselected rather than judging eligibility on your own.